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Abstract—Paraoxonase, a high density lipoprotein–associated human serum enzyme, plays a role in atherosclerosis by
protecting against lipid peroxidation. Its activity is modulated by 2 common amino acid polymorphisms at positions 192
(Gln3Arg) and 55 (Met3Leu) in the paraoxonase gene (PON1). We studied the association of PON1 polymorphisms
and myocardial infarction (MI) in a population-based study consisting of 492 cases and 518 controls matched for age,
sex, and area of residence, all living in Costa Rica. The allele frequency of PON1192Arg was higher in cases (0.27) than
in controls (0.24, P50.008), whereas that of PON155Leu was identical (0.26). Compared with PON1192Gln-Gln, the
PON1192Arg allele was associated with an increased risk of MI (odds ratio [OR] 1.36, CI 1.06 to 1.75), and this association
was independent of the PON155 polymorphism, which was not associated with MI (OR 1.10, CI 0.82 to 1.48).
Adjustment for lipid and nonlipid risk factors strengthened the association between PON1192Arg and the risk of MI (OR
1.51, CI 1.13 to 2.03). Interestingly, this association was evident only among nonsmokers (OR 1.90, CI 1.29 to 2.79):
there was no evidence of an association in smokers (OR 0.95, CI 0.57 to 1.79). The interaction between PON1192 and
smoking status was statistically significant (P50.04). Thus, the PON1192 but not the PON155 gene polymorphism is
associated with an increased risk of MI. This association is not evident among smokers. (Arterioscler Thromb Vasc
Biol. 2000;20:2120-2126.)
Key Words: coronary heart disease n genetic epidemiology n paraoxonase n antioxidants n lipoproteins
Oxidative modification of LDLs is a major contributor toatherosclerosis.1,2 By damaging endothelial cells, oxi-
dized LDL provides a nidus for monocytes that can later
become the lipid-laden foam cells prominent in the early
stages of plaque formation.1 HDLs can protect LDLs from
oxidative damage.3–5 The mechanism of this protective effect
may involve paraoxonase, an HDL-associated enzyme capa-
ble of hydrolyzing lipid peroxides.6–8
Human serum paraoxonase is a 44-kDa Ca21-dependent
glycoprotein. It remains exclusively associated with apoA-I
on HDL through a hydrophobic region at its amino termi-
nus.9,10 Paraoxonase may lower the risk of vascular disease
by destroying proinflammatory molecules formed by the
oxidation of LDL.6,11 For example, purified paraoxonase
blocks the proinflammatory effect of oxidized LDL in a
vascular cell culture system, probably by destroying oxidized
arachidonic acid derivatives in the Sn-2 position of LDL
phospholipids.8 There is a 10- to 40-fold variability in the
activity of the enzyme among individuals9 that is influenced,
in part, by differences in susceptibility to organophosphate
poisoning.12,13 This interindividual variability in activity has
been attributed to 2 polymorphisms in the coding region of
the paraoxonase gene (PON1)14,15: a Gln3Arg substitution
at position 192 (PON1192Arg) and a Met3Leu substitution at
position 55 (PON155Leu).9
The PON1192 and PON155 polymorphisms are common in
white and Asian populations, which show frequencies of
between 0.30 and 0.59 for the PON1192Arg allele16–25 and
between 0.27 and 0.91 for the PON155Leu allele.21,24,26 Para-
oxonase 192Arg is associated with various levels of activity
toward nonphysiological substrates.9,27,28 Paraoxonase
192Arg hydrolyzes paraoxon faster, and diazoxon slower,
than 192Gln does, yet the 2 alloenzymes show no difference
in activity toward other substrates, such as phenylacetate.
Most important, the ability of HDL to protect LDL from lipid
peroxidation in vitro is significantly reduced in HDL particles
containing paraoxonase 192Arg rather than 192Gln.29,30 Car-
riers of the PON155 allele show an increased activity toward
paraoxon that is independent of the PON1192Arg allele
effect.26,31
Several studies have shown a positive association between
the PON1192Arg allele and coronary disease,16,20,22,24,32,33 and
several other studies have shown no association,17–19,23,25
including 1 study of the PON155 polymorphism.21 Only 2
studies with a small sample size21,34 have evaluated the
PON1192 and the PON155 polymorphisms simultaneously. In
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diabetics, the PON1192Arg and PON155Leu alleles have both been
consistently associated with coronary disease,26,35,36 although
no association has been found with an increased risk of
diabetes.34 A lack of randomly selected control groups, small
sample sizes, and differences in criteria for case definition
may explain these inconsistent conclusions, although it is also
possible that other genetic characteristics and the particular
environmental conditions of a given population may amplify
or attenuate the effect of the PON1 gene on coronary disease.
The present study was designed to test whether the
PON1192Arg and PON155Leu alleles are associated with an
increased risk of myocardial infarction (MI) in a population-
based case-control study of Hispanics living in Costa Rica,
Central America.
Methods
Study Population
The catchment area for this case-control study included 18 counties
of Costa Rica served by the San Juan de Dios Hospital, the Rafael
Angel Caldero´n Guardia Hospital, and the Mexico Hospital, all in
San Jose´. Most of the 1.092 million people in this area are ethnically
mestizo and culturally Hispanic American.37,38 Mestizo, from the
Spanish word for mixed, connotes the admixture of whites predom-
inantly from Spain, in the case of Costa Rica, and Amerindians.
According to Costa Rican census information, admixture in Costa
Rica started as early as the 16th century, and by 1801, mestizos were
the predominant ethnic group (58% of the population), followed by
mulattos (African and white admixture, 17%), Amerindians (16%),
and whites (9%).39 The Costa Rican population of today, considered
to be 98% mestizo, is the result of 4 centuries of triracial admixture.
The exact contribution of each primary race (Amerindian, African,
and white) is unknown.37–39
All survivors of a first MI who were hospitalized between January
1994 and December 1997, who were aged ,75 years old, and who
had lived in the catchment area for at least 1 year before the event
were recruited as cases (n5531, participation 97%). Ten participants
were excluded after recruitment because they died after hospital
discharge but before data collection was completed, and 29 were
excluded because they did not have a blood sample. All cases met the
World Health Organization criteria for MI, which require typical
symptoms plus either elevations in cardiac enzyme levels or diag-
nostic changes in the ECG.40 For consistency, one study cardiologist
confirmed the diagnosis of first acute MI for all 3 hospitals before
recruitment.
One free-living control subject for each case survivor, matched for
age (65 years), sex, and area of residence, was randomly selected
from the general population by using information available at the
National Census and Statistics Bureau of Costa Rica. Control
subjects were considered ineligible if they had ever had an acute MI
or were physically or mentally unable to answer the questionnaire.
The participation rate for the controls was 90% (n5531). Thirteen
subjects were not included because they did not have a blood sample.
All study participants gave informed consent. Whenever possible,
house visits were planned so that the interviews for case-control pairs
were carried out by the same interviewer within 3 weeks of the pair
patient’s hospital discharge. The present study was approved by the
Committee on the Use of Human Subjects in Research at the Harvard
School of Public Health and by the Institute of Health Research at the
University of Costa Rica.
Data Collection
The general questionnaire included closed-end questions regarding
sociodemographic characteristics, smoking, physical activity, and
medical history (including personal history of diabetes and hyper-
tension). Self-reported diabetes and hypertension were validated by
using the definitions recommended by the Expert Committee on the
Diagnosis and Classification of Diabetes Mellitus41 and the Third
Joint National Committee on Detection, Evaluation, and Treatment
of High Blood Pressure,42 ie, a fasting capillary whole blood glucose
level $110 mg/dL (measured in the morning at the subject’s home)
or the ingestion of glucose control medications and a systolic blood
pressure $140mm Hg, a diastolic blood pressure $90 mm Hg, or the
ingestion of antihypertensive medications. The sensitivity, specific-
ity, predictive value positive, and predictive value negative were
80%, 97%, 75%, and 98%, respectively, for self-reported diabetes
and 52%, 96%, 93%, and 70%, respectively, for self-reported
hypertension. Thus, the reliability of reports of diabetes and hyper-
tension by subjects is high in the Costa Rican population. Physical
activity was determined by asking subjects about the average
frequency of several occupational and leisure-time activities during
the past year (before MI for case subjects) and the amount of time
spent on them. These activities were grouped into 6 categories
(sleeping, sitting, and light, moderate, strenuous aerobic, and stren-
uous anaerobic activities) according to intensity or to METS, defined
as the energy expenditure for sitting quietly, or ’1 kcal z kg body
wt21 z h21.43 Energy expenditure was calculated as the product of
frequency, time, and intensity and expressed as kilocalories per
kilogram per hour. This aspect of the questionnaire was validated by
checking its ability to predict fitness level (measured by the Harvard
step test) in our previous studies of cardiovascular risk factors in
residents of Puriscal, Costa Rica.44
Anthropometric measurements were collected in triplicate from
subjects wearing light clothing and no shoes. Blood samples were
obtained at the subject’s home the morning after an overnight fast
and were collected into tubes containing 0.1% EDTA. Samples were
stored at 4°C in a cooler with ice packs and transported to the field
workstation within 4 hours, where blood was centrifuged at 2500
rpm for 20 minutes at 4°C to separate the plasma from white and red
blood cells. All samples were separated into aliquots and stored at
280°C, and within 6 months, they were transported on dry ice for
analysis at the Harvard School of Public Health.
TABLE 1. Genotype and Allele Frequencies for PON1192 and
PON155 in Survivors of MI and Randomly Selected Controls
Controls
(n5518),
% (n)
Cases
(n5492),
% (n) P
PON1192
Gln-Gln 53.9 (279) 46.8 (230)
Gln-Arg 43.6 (226) 52.2 (257)
Arg-Arg 2.5 (13) 1.0 (5) 0.008
Allele frequency
Gln 0.76 0.73
Arg 0.24 0.27
PON155
Met-Met 55.6 (288) 54.3 (267)
Met-Leu 36.3 (188) 39.6 (195)
Leu-Leu 8.1 (42) 6.1 (30) 0.324
Allele frequency
Met 0.74 0.74
Leu 0.26 0.26
PON1192-PON155
Gln-Gln Met-Met 25.5 (131) 20.9 (103)
Gln-Gln Met-Leu 21.2 (110) 21.5 (106)
Gln-Gln Leu-Leu 7.3 (38) 4.3 (21)
Gln-Arg Met-Met 28.2 (146) 32.5 (160)
Gln-Arg Met-Leu 14.7 (76) 17.9 (88)
Gln-Arg Leu-Leu 0.8 (4) 1.83 (9)
Arg-Arg Met-Met 2.1 (11) 0.8 (4)
Arg-Arg Met-Leu 0.39 (2) 0.2 (1)
Arg-Arg Leu-Leu 0 0 0.04
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Laboratory Analysis
DNA was extracted with a Qiagen blood kit at the average genomic
DNA concentration of 250 mg/mL. Isolated DNA was genotyped by
polymerase chain reaction, followed by restriction endonuclease
digestion as described.9 The PON1192 and PON155 genotypes were
identified by cleavage with AlwI and NlaIII (New England Biolabs),
respectively, at 37 C° for 4 hours. The products were then run on a
10% polyacrylamide gel (45 mA current per gel) and stained with
ethidium bromide. Allele frequencies were estimated by the gene-
counting method. Plasma triglyceride, cholesterol, and HDL choles-
terol levels were assayed with enzymatic reagents (Boehringer-
Mannheim). In our laboratory, cholesterol measurements are
standardized according to the program specified by the Centers for
Disease Control and the National Heart, Lung, and Blood Institute.
Statistical Analysis
The 492 cases and 518 controls for whom there was complete
genotype information (93% and 98%, respectively, of the total study
population) were included in the analysis, which was performed with
software from Statistical Analysis Systems. After the data had been
checked for errors, outliers, and distributions, crude means and
frequencies for health characteristics and potential confounders were
compared by using 2-sided t tests and the x2 test. Triglyceride values
were normalized by loge transformation, and data are presented as a
geometric mean6approximate SD.
The presence or absence of the PON1192Arg and PON155Leu alleles
was used to define 2 groups for the gene effect, with the
PON1192Gln-Gln and the PON155Met-Met genotypes used as reference
categories. Multiple nonconditional logistic regression was used
to calculate odds ratios (ORs) with 95% CIs for case status. The
TABLE 2. General Characteristics and Plasma Lipids in Survivors of MI and Randomly
Selected Controls by PON1 Genotype
PON1192Gln PON1192Arg
Controls
(n5279)
Cases
(n5230)
Controls
(n5239)
Cases
(n5262)
Age, y 5760.6 5760.7 5660.7 5760.7
Sex, % female 23 25 28 24
Area, % living in urban area 56 53 55 57
Current smokers, % yes* 24 47§ 32 43§
Diabetes, % yes† 12 24§ 11 23§
Hypertension, % yes† 28 41§ 25 43§
Angina, % yes‡ 4 12§ 6 11¶
Monthly income, US$ 569628 427630§ 546630 501629
Waist-to-hip ratio 0.9360.004 0.9560.004§ 0.9460.004 0.9560.004§
Physical activity,
kcal z kg21 z h21
1.8760.06 1.6460.06\ 1.7560.06 1.7460.06
Triglyceride, mg/dL 2056100 2436107§ 2086125 2386108\
Total cholesterol, mg/dL 201639 195641 199640 195639
HDL cholesterol, mg/dL 42612 35611§ 42611 37614§
PON155Met PON155Leu
Controls
(n5288)
Cases
(n5267)
Controls
(n5230)
Cases
(n5225)
Age, y 5760.7 5760.7 5660.7 5760.7
Sex, % female 27 24 23 25
Area, % living in urban area 59 55 52 55
Current smokers, % yes* 30 46§ 25 43§
Diabetes, % yes† 11 23§ 12 24§
Hypertension, % yes† 28 41\ 24 43§
Angina, % yes‡ 4 9\ 5 14§
Monthly income, US$ 550627 491628 569630.4 437631\
Waist-to-hip ratio 0.9360.003 0.9460.004 0.9360.004 0.9660.004§
Physical activity,
kcal z kg21 z h
1.8260.06 1.8060.06 1.8060.06 1.5660.06\
Triglyceride, mg/dL 2106122 2416108§ 202697 2396108\
Total cholesterol, mg/dL 202640 197643 198639 192635
HDL cholesterol, mg/dL 43612 36612§ 41611 36613§
Values are mean6SD. PON1192Arg includes the PON1192Gln-Arg and PON1192Arg-Arg genotypes. PON155Leu includes the
PON155Met-Leu and PON155Leu-Leu genotypes.
*Self-reported smoking $1 cigarette/d.
†Self-reported diabetes and hypertension.
‡Evaluated by Rose questionnaire (group comparison by x2 analysis).
§P#0.001, \P#0.01, and ¶P#0.05 vs controls with same genotype.
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presence of the PON1192Arg and PON155Leu alleles was compared
with their absence. The distribution among controls of continuous
variables (income, physical activity, waist-to-hip ratio, and tri-
glyceride, HDL cholesterol, and total cholesterol levels) was used
to compute quintile categories that were included in the multiple
logistic regression models as covariates. The presence of diabetes,
hypertension, and angina was compared with the absence of these
diseases (reference). Subjects who smoked $1 cigarette per day
were defined as current smokers and were compared with past
smokers and those who had never smoked grouped together
(referent category).
The first model included the polymorphisms of PON1192 and
PON155 and the covariates age, sex, and area of residence (urban,
periurban, or rural). Two additional models also included smok-
ing, income, physical activity, waist-to-hip ratio, diabetes, hyper-
tension, angina, and triglyceride, cholesterol, and HDL cholester-
ol levels. Data for covariates are presented for the highest
compared with the lowest quintile, for the presence compared
with the absence of disease, and for smokers compared with
nonsmokers. The cut points for the lowest versus highest quintiles
among covariates were #$192 and $$871 for monthly income,
#1.14 and $2.33 kcal z kg21 z h21 for physical activity, #0.88 and
$1.00 for waist-to-hip ratio, #128 and $263 mg/dL for triglyc-
eride, #33 and $49 mg/dL for HDL cholesterol, and #128 and
$263 mg/dL for total cholesterol. All covariates were also tested
for their potential as effect modifiers. Because these analyses
revealed a significant interaction between the PON1192 poly-
morphism and smoking status, the effect of the PON1192 poly-
morphism was investigated in additional analyses in smokers and
nonsmokers separately. We also examined the PON1192 poly-
morphism–smoking interaction in a model of 4 groups in which
the referent category, nonsmokers with PON1192Gln-Gln, was com-
pared simultaneously with nonsmokers with PON1192Arg, smokers
with PON1192Gln-Gln, and smokers with PON1192Arg. Values of
P,0.05 (2-sided) were the mark of statistically significant
differences.
Results
Table 1 shows the genotype and allele frequencies for
PON1192 and PON155 in cases and controls. The presence of
the PON1192Arg allele was more common in cases than in
controls (P50.008). No difference in genotype distribution
was found for the PON155 polymorphism. When the PON1192
and PON155 genotypes were analyzed together, the frequency
of the PON192Arg allele was higher in cases irrespective of their
PON155 genotype (P50.04).
General characteristics in MI cases and randomly selected
controls by PON1 genotype are presented in Table 2. Waist-
to-hip ratio, smoking, and history of diabetes, hypertension,
and angina were significantly higher in cases than in controls
regardless of genotype. In both PON1 genotypes, compared
with controls, cases had higher triglyceride concentrations,
lower HDL cholesterol concentrations, and similar total
cholesterol concentrations. There was no significant differ-
ence between genotypes for any parameter within cases or
controls.
Table 3 shows the ORs for the presence compared with the
absence of the PON1192Arg and PON155Leu alleles. The presence
of PON1192Arg was associated with an increased risk of MI
(OR 1.36, CI 1.06 to 1.75). This association did not change
and remained statistically significant in a multivariate model
that included nonlipid risk factors. The addition of an adjust-
ment for lipid risk factors strengthened the association (OR
1.51, CI 1.13 to 2.03). In the same models, the PON155Leu
polymorphism was not associated with risk of MI (OR 1.12,
CI 0.87 to 1.44). Among the covariates, higher income and
HDL cholesterol were associated with lower risk of MI.
Smoking, high plasma triglyceride levels, and history of
diabetes, hypertension, and angina were associated with an
increase in the risk of MI. Because of the potential for sex
differences to confound the data analysis, we repeated the
analysis in males only. The results for men were similar to
those for the whole population, by univariate or multivariate
analysis. For PON1192Arg, the OR was 1.63, with the CI 1.17 to
2.27; for PON155Leu, the OR was 0.98, with the CI 0.70 to 1.37
(adjusting for covariates in model 3).
An association between PON1192Arg and MI (Table 4) was
evident only among nonsmokers (OR 1.64, CI 1.19 to 2.26)
compared with smokers (OR 0.89, CI 0.58 to 1.38), and it was
strengthened by an adjustment for lipid and nonlipid risk
factors. The interaction between PON1192 and smoking status
was statistically significant (P50.04). No association be-
tween PON155Leu and MI was detected in smokers or non-
smokers. Because stratification by smoking changed the sex
distribution, we repeated the analysis in men only. The results
for men were similar to those for the entire population: OR
TABLE 3. ORs for MI Associated With Presence of PON1192Arg
and PON155Leu Alleles
Model 1 Model 2 Model 3
PON1192Arg 1.36‡ 1.35‡ 1.51\
(1.06–1.75) (1.03–1.77) (1.13–2.03)
PON155Leu 1.12 1.08 1.10
(0.87–1.44) (0.82–1.42) (0.82–1.48)
Nonlipid risk factors
Smoking (yes)* 2.40§ 2.28§
(1.79–3.23) (1.66–3.13)
Income† 0.48\ 0.52‡
(0.29–0.78) (0.31–0.89)
Physical activity† 0.82 0.89
(0.53–1.25) (0.57–1.42)
Waist-to-hip ratio† 1.38 0.84
(0.83–2.31) (0.48–1.47)
Diabetes (yes) 2.21§ 2.34§
(1.50–3.26) (1.54–3.55)
Hypertension (yes) 2.09§ 1.87§
(1.54–2.83) (1.36–2.59)
Angina (yes) 2.37\ 2.50\
(1.40–4.01) (1.44–4.34)
Lipid risk factors
Triglyceride† 4.29§
(2.35–7.82)
HDL cholesterol† 0.22§
(0.13–0.37)
Total cholesterol† 1.02
(0.34–3.00)
Values are ORs (with CIs in parentheses). The absence of the PON1192Arg and
PON155Leu alleles was used as the referent category. All models include the
matching variables age, sex, and area of residence.
*Nonsmokers and past smokers were used as the referent category. †ORs
are given for the highest quintile compared with the lowest.
‡P,0.05, §P,0.0001, and \P,0.01.
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1.90 (CI 1.29 to 2.80) for PON1192Arg and OR 1.09 (CI 0.74 to
1.60) for PON155Leu.
The Figure shows the association between PON1192Arg
and risk of MI when nonsmokers with the PON1192Gln-Gln
genotype were used as the referent category. Smokers had
an increased risk of MI regardless of their PON1192
genotype: OR 2.66 (CI 1.75 to 4.05) for PON1192Gln-Gln and
OR 2.60 (CI 1.72 to 3.9) for PON1192Arg. The association
between PON1192Arg and risk of MI was evident only among
nonsmokers, although the magnitude of this effect, OR
1.52 (CI 1.08 to 2.15), was considerably smaller than the
effect of smoking on risk of MI.
Discussion
Our data show that the PON1192Arg allele was associated
with a 36% increase in the risk of MI. This association was
independent of the PON155 polymorphism, which was not
associated with MI. An adjustment for lipid and nonlipid
risk factors strengthened the association between
PON1192Arg and the risk of MI. The association that we
found between PON1192Arg and MI is consistent with the
results of several studies16,20,22,24,32,33,35,36 but not all.17–
19,23,25 These discrepancies could be due in part to the
selection criteria of the control group, to differences in
case definition, and to a lack of a population-based control
group. These limitations apply to negative and positive
studies, yet in the Etude Cas-Temoins sur l’Infarctus du
Myocarde (ECTIM) study, the largest population-based
study (642 patients and 701 age-matched controls), no
association between PON1192Arg and MI was found.19 We
hypothesize that environmental or behavioral factors could
mask or induce the atherogenic potential of the PON1192Arg
allele. We believe that our findings are an example of a
widespread phenomenon of modulation of genetic effects
by environmental factors that vary among populations.
Further studies must include and investigate as much
information as possible on environmental factors that
could modulate genetic effects.
Conflicting results are also found for the PON155 poly-
morphism. One study in French diabetic patients found a
significant association between the PON155 polymorphism
and coronary disease.26 The PON155 polymorphism was not
associated with risk of MI in the present study and in one
previous report.21
The mechanism mediating the association between the
PON1192Arg allele and an increased risk of MI is not known. In
vitro studies show that HDL from carriers of the PON1192Arg
allele is less effective in decreasing the accumulation of LDL
lipid peroxides.29,30 Perhaps this reduction in LDL protection
(or in some other yet-to-be-identified activity conferred by
PON1) explains the atherogenic effect of PON1192Arg observed
in the present and other studies.16,20,22,24,32,33
HDL may play a significant role in the effect of PON1
on coronary disease. HDL cholesterol levels and paraoxo-
nase protein levels are significantly correlated.45 In one
study, the PON1192Arg allele was associated with lower
HDL cholesterol levels,46 but this was not confirmed in
other studies.35,45,47 We did not find an association between
PON1 polymorphisms and HDL cholesterol levels or a
significant interaction between HDL cholesterol and PON1
(data not shown).
A significant interaction between smoking status and
genotype revealed that the presence of PON1192Arg was asso-
ciated with a 64% increase in the risk of MI among nonsmok-
ers in the present our study. There was no evidence of this
association in smokers. It is possible that these results can be
explained by differential survival among smokers. On the
other hand, there is a biological basis for these results.
Cigarette smoke extract decreases paraoxonase activity
against nonphysiological substrates,48 and it may also reduce
PON1 activities that are involved in cardioprotection. Thus,
the deleterious effects of cigarette smoke may equalize or
outweigh the differences in potentially positive enzyme
activities conferred by the PON1 genotype. However, be-
cause we did not measure PON1 activity in the present study,
we cannot determine whether this is the mechanism respon-
sible for our results.
OR of MI associated with presence of PON1192Arg allele in smok-
ers and nonsmokers, where nonsmokers with PON1192Gln-Gln are
used as reference. Nonsmokers include past smokers.
TABLE 4. ORs for MI Associated With Presence of PON1192Arg
and PON155Leu Alleles by Smoking Status
Nonsmokers Smokers
Model 1
PON1192Arg 1.64* 0.89
(1.19–2.26) (0.58–1.38)
PON155Leu 1.13 1.15
(0.82–1.57) (0.74–1.79)
Model 2
PON1192Arg 1.70* 0.86
(1.19–2.43) (0.54–1.36)
PON155Leu 1.05 1.14
(0.74–1.50) (0.71–1.81)
Model 3
PON1192Arg 1.90† 0.95
(1.29–2.79) (0.57–1.79)
PON155Leu 1.09 1.07
(0.74–1.59) (0.64–1.79)
Values are ORs (with CIs in parentheses). The absence of the PON1192Arg and
PON155Leu alleles was used as the referent category. See Table 3 for covariates
included in each model. The nonsmoker category includes past smokers. Value
of P for PON1192 genotype–smoking interaction is 0.04 and for PON155 genotype
smoking interaction is 0.9.
*P,0.005 and †P,0.001.
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Further work is needed to clarify the mechanisms
underlying the gene-environment interaction identified in
the present study and to uncover other environmental
factors that modify the effect of the PON1 genotype on
coronary disease.
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